27,380 Alzheimer's and dementia studies in plain English, each scored out of 100.
Trisomy 21 (Down syndrome) is associated with a high incidence of Alzheimer disease and with deficits in cholinergic function in humans. 3 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Down syndrome, caused by the trisomy of chromosome 21, is a complex condition characterized by a number of phenotypic features, including reduced neuron number and synaptic plasticity, early Alzheimer disease-like neurodegeneration, craniofacial dysmorphia, heart development defects, increased incidence of childhood leukemia, and powerful suppression of the incidence of most solid tumors. 3 key findings →
Participants: 1,661 Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Our results provide further insights into the architecture and underlying mechanisms of complex rearrangements on acrocentric chromosomes. 3 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Osteoclasts require coordinated co-stimulation by several signaling pathways to initiate and regulate their cellular differentiation. 4 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Diverse pathogens are detected in Alzheimer's disease (AD) brains. 4 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Fluid biomarkers improve the diagnostic accuracy in dementia and provide an objective measure potentially useful as a therapeutic response in clinical trials. 4 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
In this study, we aimed to compare cerebrospinal fluid (CSF) levels of total tau (t-tau), phosphorylated tau (p-tau(181)) and positron emission tomography with (18)F-fluorodeoxyglucose (FDG-PET) in the differential diagnosis of Alzheimer's disease (AD) under clinical conditions. 4 key findings →
Design: cross-sectional Participants: 24 Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Data from the Canadian Study of Health and Aging (CSHA) were used to examine the relation between severity of Alzheimer's disease, as measured by the Mini-Mental State Examination (MMSE), and costs of caring. 4 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
With increased life expectancy worldwide, there is an urgent need for improving preventive measures that delay the development of age-related degenerative diseases. 4 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Increasing costs of institutional care for the aged have occasioned a variety of government cost containment measures. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Thirty-three per cent of the hospital beds were occupied with ALC patients; 63% had a diagnosis of dementia. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
This study found that awareness of home-based nursing, interest in home-based care for older people, and attitudes toward filial responsibility significantly influence the intention to work in home-based care. 5 key findings →
Design: cross-sectional Participants: 236 Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
The results were consistent for both nursing homes and data were aggregated. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Mammogram utilization was 16% higher (Prevalence Ratio [PR] 1.16; 95% CI: 1.05, 1.29) among Medicare Advantage enrollees with dementia, compared to their counterparts in fee-for-service Medicare. 5 key findings →
Design: cross-sectional Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Our results show that MA enrollees in PR have six percentage points higher ADRD rates than their US counterparts. 2 key findings →
Participants: 123,609 Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Overall, 3.3% of beneficiaries switched to MA annually. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Among the 1,035 patients in our dataset, 176 (17%) had a dementia diagnosis. 5 key findings →
Participants: 1,035 Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
The number of individuals with anorexia ranged from 317,964 to 328,977 per year, a mean annual prevalence rate of 1.1%. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Conversely, longer travel times to service providers were linked to use of fewer community-based services (B = -0.21, p < .001). 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Geographic and temporal variation in occurrence of dementia within the US has received little attention despite its importance for generation of new etiologic hypotheses and health services research. 2 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
The burden of perioperative organ injury in China is significant even at a national level. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Across racial/ethnic groups, 33%-43% in DS and 43%-50% in non-DS used specialists; 47%-55% in DS and 41%-48% in non-DS used ADRD drugs. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Our study highlights the potential of Decipher‐AI for screening undiagnosed cognitive impairment in primary care. 3 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Patients (N = 2,512) receiving lecanemab infusion had a mean age of 75.4 (standard deviation = 5.7) years as compared to 80.8 (8.9) years in patients with MCI/AD not receiving the infusion. 5 key findings →
Participants: 2,512 Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
The analyses of the community‐based U.S. POINTER indicate that AA/B individuals present differences in AD and related dementia biomarker values. nHW had higher fully adjusted cognitive scores. 5 key findings →
Participants: 644 Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Free full text links and the Full text may need a subscription label come from Unpaywall, Europe PMC and OpenAlex records of free copies, checked 10 Oct 2026. A study with neither is unknown, not paywalled.
This is alzhub's own score. It is not an official metric, not an impact factor, and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a scientist can tell a landmark trial from a conference abstract without having to already know the difference. Every point comes from one of 20 components, all of them printed on the study itself, so you can disagree with our arithmetic rather than having to trust the total.
Journals are placed in ordered tiers, never given a numeric impact factor — we could not verify current impact factors from a source we control, and an invented one would be worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science, Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed journal. A separate part scores how much the journal's own papers are cited, which tells the tier-3 journals apart.
Two rules we don't bend. First, we never fill in a missing value: if a record does not state a sample size or a design, that component scores zero, and if we simply have no data for a part, such as a citation count, that part is left out and the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed article is capped at 16/100 and carries a warning chip — so a conference abstract or a company press release can never outrank a peer-reviewed paper, no matter how good it looks.
We rank a rigorous null result — a good trial showing that something does not work — above an early positive finding. Someone deciding whether to buy a supplement is served by that, and the rigour is already counted by the design and journal components.
The score is computed from the published data alone and is reproducible: the same file always yields the same numbers.
See the whole rubric drawn out → — four charts covering all 27,380 studies: how the scores are spread and where the cap bites, which of the 20 components the library is strong and weak on, which subjects rest on stronger evidence, and what kinds of study each subject is actually built from.
This is a large sample of the Alzheimer's literature, not an exhaustive index of it. It holds 27,380 records, built mostly from automated pulls of Europe PMC (60.6% of the library) and OpenAlex (18.6%), plus smaller pulls from PubMed, Crossref and medRxiv. If a study, a drug, or a finding isn't here, that is not evidence it doesn't exist in the literature — it may simply not have been pulled in yet.
1,032 records (3.8% of the library) are not peer-reviewed — 962 of those are preprints posted before any journal review, and the rest are conference abstracts, regulatory notices and reports. Every study card on this page states its status plainly, and the score above is capped for anything that isn't a peer-reviewed article.
See the full, machine-readable breakdown of this library's coverage →